REMEGEN (09995) is recommended to adopt the A-share stock incentive plan in 2023.
Connect global capital markets
REMEGEN (09995) announced that the board of directors recommends adopting the 2023 A-share stock incentive plan, planning to grant approximately 1.7831 million restricted stocks to the incentive beneficiaries. Upon the initial grant, 1.43245 million restricted stocks will be allocated, and approximately 0.3506 million restricted stocks will be reserved. The grant price (including reserved grants) is set at RMB 49.77 per A-share.
Related Articles

JUTAL OIL SER (03303) plans to issue approximately 356 million new shares through a rights issue.

Beijing Science Sun Pharmaceutical (300485.SZ) subsidiary withdraws a drug registration application.

Subsidiary of FESCO Group Co., Ltd (600861.SH) obtains 396 million yuan industry policy funds.
JUTAL OIL SER (03303) plans to issue approximately 356 million new shares through a rights issue.

Beijing Science Sun Pharmaceutical (300485.SZ) subsidiary withdraws a drug registration application.

Subsidiary of FESCO Group Co., Ltd (600861.SH) obtains 396 million yuan industry policy funds.

RECOMMEND

State Reform Fund And Three Major Banks Backstop Voyah As It Secures Hong Kong’s First Auto IPO This Year
20/03/2026

Hong Kong IPO Irregularities Surface As Corner Placements And Retail Losses Emerge, Haizhi Technology Implicated
20/03/2026

Gold And Silver Experience Sharp Sell‑Off As Global Rate‑Hike Expectations Intensify
20/03/2026


